Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma

• Status: Terminated
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate whether treatment with rituximab plus sargramostim will be more effective than rituximab alone.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genzyme, a Sanofi Company
• Treatments: Molgramostim; Rituximab; Sargramostim

Criteria

Inclusion Criteria (abbreviated list):

• Relapsed follicular B-cell lymphoma

• One or more previous therapies for non-Hodgkin's

• At least one measurable tumor by CT scan or MRI

• Additional criteria to be determined at screening visit

Exclusion Criteria (abbreviated list):

• Rituximab refractory (less than 6 months from last treatment with rituximab to relapse)

• Currently receiving treatment for another cancer

• Infection currently being treated

• Active Hepatitis B

• History of HIV infection

• Pregnant

• Additional criteria to be determined at screening visit